The Silverfern Group Makes Transformative Follow-on Investment into American Medical Technologies

New York, New York, March 31, 2021 – The Silverfern Group, an investment management firm making direct investments in middle market private equity globally, today announced that it has made a transformative follow-on investment into American Medical Technologies (“AMT”) to fund the acquisition of RestorixHealth (“Restorix”).

AMT, based in Irvine, CA is a leading provider of post-acute care programs, offering wound care services and other ancillary supplies to senior patients in long-term care settings (i.e., skilled nursing facilities (“SNF”)) throughout the United States. AMT manages the treatment of more than 250,000 wounds annually and offers ancillary services in ostomy, urology and tracheostomy services and supplies. AMT is the largest wound care service provider to the post-acute care market in the United States.

Restorix operates 236 wound centers in partnership with hospitals across 32 states and in-home wound care durable medical equipment (“DME”) and physician service capabilities across two states. Headquartered in White Plains, N.Y., Restorix manages outpatient wound centers and provides on-site staff on behalf of hospitals, including advanced treatment modalities, including debridement, hyperbaric oxygen treatment, evaluations, negative pressure wound therapy, and cellular and tissue-based products to patients.

Restorix’s rapidly growing offerings in wound care supplies and at-home physician services will be strengthened by AMT’s existing platform, commercial contract footprint and supplies expertise. In addition, AMT will leverage Restorix’s at-home platforms to accelerate growth. AMT is a portfolio company of The Silverfern Group and One Equity Partners.

Following completion of the investment, Silverfern Managing Partner Clive Holmes commented “The Restorix transaction demonstrates Silverfern’s commitment to transformative follow-on investments for high growth acquisition opportunities for our portfolio companies. AMT was acquired by Silverfern and One Equity Partners in August 2020.”


About AMT

Founded in 1990 AMT has evolved into a full service provider of post-acute care programs, offering wound care and other ancillary supplies to senior patients in long-term care settings including SNFs in the United States. AMT is a leader in delivering outcome driven senior care programs and is an accredited supplier of Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) as well as a participating Medicare Part B provider. With 25 years of industry experience, AMT assists providers by supplying advanced wound care, ostomy, urological, and tracheostomy products to facilitate the delivery of high-quality patient care.

About RestorixHealth

RestorixHealth (RXH) is a leading developer and operator of advanced wound healing centers and provider of wound healing direct-care services. Dedicated to healing wounds, saving limbs, and optimizing patient outcomes, RestorixHealth provides its patients and partners with custom, advanced wound healing solutions that increase the access to care, lower direct care costs, reduce hospital admissions, improve outcomes, and increase patient satisfaction. RestorixHealth treats patients at various locations, including hospital-based centers, nursing homes, skilled facilities and in patients’ homes. Additionally, through the company’s DME service line, wound healing supplies are shipped to patient homes throughout the nation. Please visit ​

About Silverfern

Silverfern is a global middle-market investment management firm. From its offices in Greenwich, Frankfurt and Sydney, its experienced, cohesive team of senior investment professionals makes investments in global middle-market private equity. Targeting $25 million to $50 million equity per investment in partnership with qualified local investment partners, whom we select for their specific industry knowledge and local market experience, Silverfern seeks to invest in buyouts, build-ups, acquisitions, growth equity and recapitalizations worldwide. Silverfern’s investment strategy seeks to mitigate systemic risk in its portfolio by opportunistically pursuing attractive risk-adjusted returns on a global basis, while at the same time seeking to manage local/market risk through its strategy to partner with qualified, local, investment partners on each of its investments. Silverfern is currently investing from Silverfern Global Opportunities Fund III. Additional information is available at


Media Contact:
Robert Spittler
+49 173 25 37 465